Zachary T. Bloomgarden, MD, Editor of the Journal of Diabetes and a Clinical Professor at the Mount Sinai School of Medicine, provides a critical analysis of the recent FDA decision of keeping Avandia on the market.

Disclosure:
Speaker’s Bureau: Merck, NovoNordisk, GSK
Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel
Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories
Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker

Reading:
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G; ADOPT Study Group.Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4.

DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR.Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006 Oct 12;355(15):1551-62. Epub 2006 Sep 15.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5. Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis.